Literature DB >> 21461632

Acute antibody-mediated rejection in paediatric renal transplant recipients.

Birgitta Kranz1, Reinhard Kelsch, Eberhard Kuwertz-Bröking, Verena Bröcker, Heiner H Wolters, Martin Konrad.   

Abstract

Acute antibody-mediated rejections (aAMR) after renal transplantation are defined by rapidly deteriorating graft function, detection of donor-specific antibodies (DSA) and characteristic histological features. In adults, anti-rejection strategies comprise intravenous immunoglobulin (IVIG), steroid pulses, plasmapheresis and rituximab. Data of children with aAMR are scarce. We report four episodes of aAMR in three children (aged 10, 10 and 11 years respectively) occurring early after renal transplantation. Pre-transplant complement-dependent cytotoxicity crossmatches were negative; in the case of re-transplantation repeated antigens were excluded. Basic immunosuppression comprised cyclosporine A, MMF and steroids. All four rejection episodes were histologically proven and associated with acute renal failure. De novo DSAs were detected in two aAMRs; one patient was additionally tested positive for AT1-receptor antibodies. All aAMRs were treated with steroid pulses, tacrolimus, MMF, IVIG, plasmapheresis and one single dose of rituximab. Despite therapy one graft was lost; in the remaining three cases kidney function re-established within 1-8 weeks. At follow-up, 14, 15 and 22 months' post-rejection their GFRs were 65, 88 and 105 ml/min/1.73 m(2) respectively. A combined therapy of steroid pulses, IVIG, plasmapheresis and rituximab is potentially effective in the treatment of aAMR in children.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21461632     DOI: 10.1007/s00467-011-1864-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  21 in total

Review 1.  Antibody-mediated renal allograft rejection: diagnosis and pathogenesis.

Authors:  Robert B Colvin
Journal:  J Am Soc Nephrol       Date:  2007-03-14       Impact factor: 10.121

2.  Rituximab for humoral rejection after kidney transplantation: an update.

Authors:  Lionel Rostaing; Céline Guilbeau-Frugier; Nassim Kamar
Journal:  Transplantation       Date:  2009-04-27       Impact factor: 4.939

3.  Diagnosis and treatment of acute humoral kidney allograft rejection.

Authors:  A M Gomes; S Pedroso; L S Martins; J Malheiro; J R Viscayno; J Santos; L Dias; A C Henriques; A M Sarmento; A Cabrita
Journal:  Transplant Proc       Date:  2009-04       Impact factor: 1.066

4.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

Authors:  G J Schwartz; G B Haycock; C M Edelmann; A Spitzer
Journal:  Pediatrics       Date:  1976-08       Impact factor: 7.124

5.  Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation.

Authors:  Sebastian Riethmüller; Sylvie Ferrari-Lacraz; Markus K Müller; Dimitri A Raptis; Karine Hadaya; Barbara Rüsi; Guido Laube; Gregory Schneiter; Thomas Fehr; Jean Villard
Journal:  Transplantation       Date:  2010-07-27       Impact factor: 4.939

6.  Rituximab therapy for acute humoral rejection after kidney transplantation.

Authors:  Stanislas Faguer; Nassim Kamar; Céline Guilbeaud-Frugier; Marylise Fort; Anne Modesto; Arnaud Mari; David Ribes; Olivier Cointault; Laurence Lavayssière; Joelle Guitard; Dominique Durand; Lionel Rostaing
Journal:  Transplantation       Date:  2007-05-15       Impact factor: 4.939

7.  Impact of rituximab therapy for treatment of acute humoral rejection.

Authors:  Z Kaposztas; H Podder; S Mauiyyedi; O Illoh; R Kerman; M Reyes; V Pollard; B D Kahan
Journal:  Clin Transplant       Date:  2009 Jan-Feb       Impact factor: 2.863

8.  A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection.

Authors:  William R Mulley; Fiona J Hudson; Brian D Tait; Alison M Skene; John P Dowling; Peter G Kerr; John Kanellis
Journal:  Transplantation       Date:  2009-01-27       Impact factor: 4.939

9.  Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation.

Authors:  C Lefaucheur; C Suberbielle-Boissel; G S Hill; D Nochy; J Andrade; C Antoine; C Gautreau; D Charron; D Glotz
Journal:  Contrib Nephrol       Date:  2008-10-31       Impact factor: 1.580

Review 10.  Advances in diagnosing and managing antibody-mediated rejection.

Authors:  Stanley C Jordan; Nancy Reinsmoen; Alice Peng; Chih-Hung Lai; Kai Cao; Rafael Villicana; Mieko Toyoda; Joseph Kahwaji; Ashley A Vo
Journal:  Pediatr Nephrol       Date:  2010-01-14       Impact factor: 3.714

View more
  8 in total

Review 1.  Tandem hemodialysis and plasma exchange.

Authors:  Guido Filler; William F Clark; Shih-Han S Huang
Journal:  Pediatr Nephrol       Date:  2013-09-11       Impact factor: 3.714

Review 2.  Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013.

Authors:  Caitlin E Carter; Nadine M Benador
Journal:  Pediatr Nephrol       Date:  2013-06-29       Impact factor: 3.714

Review 3.  Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management.

Authors:  Yolanda W Ng; Manpreet Singh; Minnie M Sarwal
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

Review 4.  Acute and chronic antibody-mediated rejection in pediatric kidney transplantation.

Authors:  Lars Pape; Jan U Becker; Stephan Immenschuh; Thurid Ahlenstiel
Journal:  Pediatr Nephrol       Date:  2014-05-28       Impact factor: 3.714

5.  Role of therapeutic apheresis in the treatment of pediatric kidney diseases.

Authors:  Shweta Shah; Catherine Joseph; Poyyapakkam Srivaths
Journal:  Pediatr Nephrol       Date:  2021-05-15       Impact factor: 3.714

Review 6.  Biologics in renal transplantation.

Authors:  Ryszard Grenda
Journal:  Pediatr Nephrol       Date:  2014-07-26       Impact factor: 3.714

Review 7.  Issues in solid-organ transplantation in children: translational research from bench to bedside.

Authors:  Steven E Lipshultz; Jayanthi J Chandar; Paolo G Rusconi; Alessia Fornoni; Carolyn L Abitbol; George W Burke; Gaston E Zilleruelo; Si M Pham; Elena E Perez; Ruchika Karnik; Juanita A Hunter; Danielle D Dauphin; James D Wilkinson
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

8.  Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation.

Authors:  Samuele Iesari; Quirino Lai; Evaldo Favi; Francesco Pisani
Journal:  Yonsei Med J       Date:  2017-05       Impact factor: 2.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.